|
Gene: SEZ6L2 |
Gene summary for SEZ6L2 |
Gene summary. |
Gene information | Species | Human | Gene symbol | SEZ6L2 | Gene ID | 26470 |
Gene name | seizure related 6 homolog like 2 | |
Gene Alias | BSRPA | |
Cytomap | 16p11.2 | |
Gene Type | protein-coding | GO ID | GO:0005575 | UniProtAcc | Q6UXD5 |
Top |
Malignant transformation analysis |
Identification of the aberrant gene expression in precancerous and cancerous lesions by comparing the gene expression of stem-like cells in diseased tissues with normal stem cells |
Malignant transformation involving gene list. |
Entrez ID | Symbol | Replicates | Species | Organ | Tissue | Adj P-value | Log2FC | Malignancy |
26470 | SEZ6L2 | LZE4T | Human | Esophagus | ESCC | 3.45e-04 | 4.85e-02 | 0.0811 |
26470 | SEZ6L2 | LZE5T | Human | Esophagus | ESCC | 7.02e-03 | 3.06e-01 | 0.0514 |
26470 | SEZ6L2 | LZE7T | Human | Esophagus | ESCC | 1.48e-05 | 5.23e-01 | 0.0667 |
26470 | SEZ6L2 | LZE8T | Human | Esophagus | ESCC | 2.44e-06 | 1.18e-01 | 0.067 |
26470 | SEZ6L2 | LZE20T | Human | Esophagus | ESCC | 4.42e-02 | 1.57e-01 | 0.0662 |
26470 | SEZ6L2 | LZE24T | Human | Esophagus | ESCC | 2.52e-06 | 2.66e-01 | 0.0596 |
26470 | SEZ6L2 | LZE6T | Human | Esophagus | ESCC | 2.31e-02 | 2.72e-01 | 0.0845 |
26470 | SEZ6L2 | P2T-E | Human | Esophagus | ESCC | 3.80e-05 | 1.47e-01 | 0.1177 |
26470 | SEZ6L2 | P4T-E | Human | Esophagus | ESCC | 7.88e-33 | 6.99e-01 | 0.1323 |
26470 | SEZ6L2 | P5T-E | Human | Esophagus | ESCC | 5.87e-09 | 1.21e-01 | 0.1327 |
26470 | SEZ6L2 | P8T-E | Human | Esophagus | ESCC | 4.48e-20 | 5.07e-01 | 0.0889 |
26470 | SEZ6L2 | P10T-E | Human | Esophagus | ESCC | 4.72e-13 | 1.14e-01 | 0.116 |
26470 | SEZ6L2 | P11T-E | Human | Esophagus | ESCC | 2.35e-15 | 7.25e-01 | 0.1426 |
26470 | SEZ6L2 | P12T-E | Human | Esophagus | ESCC | 2.16e-02 | 8.40e-02 | 0.1122 |
26470 | SEZ6L2 | P16T-E | Human | Esophagus | ESCC | 8.42e-14 | 3.53e-01 | 0.1153 |
26470 | SEZ6L2 | P17T-E | Human | Esophagus | ESCC | 2.26e-04 | 3.18e-01 | 0.1278 |
26470 | SEZ6L2 | P20T-E | Human | Esophagus | ESCC | 9.83e-04 | 5.09e-02 | 0.1124 |
26470 | SEZ6L2 | P21T-E | Human | Esophagus | ESCC | 6.42e-07 | 1.04e-02 | 0.1617 |
26470 | SEZ6L2 | P22T-E | Human | Esophagus | ESCC | 5.96e-28 | 5.19e-01 | 0.1236 |
26470 | SEZ6L2 | P23T-E | Human | Esophagus | ESCC | 3.72e-13 | 2.93e-01 | 0.108 |
Page: 1 2 3 4 5 6 |
Transcriptomic changes along malignancy continuum. |
∗log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage. |
Top |
Malignant transformation related pathway analysis |
Find out the enriched GO biological processes and KEGG pathways involved in transition from healthy to precancer to cancer |
Figure of enriched GO biological processes. |
Tissue | Disease Stage | Enriched GO biological Processes |
Colorectum | AD | |
Colorectum | SER | |
Colorectum | MSS | |
Colorectum | MSI-H | |
Colorectum | FAP |
∗Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust). |
Page: 1 2 3 4 5 6 7 8 9 |
Enriched GO biological processes. |
GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
Page: 1 |
Enriched KEGG pathways. |
Pathway ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | qvalue | Count |
Page: 1 |
Top |
Cell-cell communication analysis |
Identification of potential cell-cell interactions between two cell types and their ligand-receptor pairs for different disease states |
Ligand | Receptor | LRpair | Pathway | Tissue | Disease Stage |
Page: 1 |
Top |
Single-cell gene regulatory network inference analysis |
Find out the significant the regulons (TFs) and the target genes of each regulon across cell types for different disease states |
TF | Cell Type | Tissue | Disease Stage | Target Gene | RSS | Regulon Activity |
∗The dot plots of a searched regulon are shown for all cell subpopulations in each disease state of each tissue based on the regulon specific score inferred using pySCENIC and by calculating the average expression. |
Page: 1 |
Top |
Somatic mutation of malignant transformation related genes |
Annotation of somatic variants for genes involved in malignant transformation |
Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
SEZ6L2 | SNV | Missense_Mutation | c.1195G>A | p.Glu399Lys | p.E399K | protein_coding | deleterious(0.01) | probably_damaging(0.992) | TCGA-A8-A094-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD | ||
SEZ6L2 | SNV | Missense_Mutation | rs764439495 | c.2516G>A | p.Arg839Gln | p.R839Q | protein_coding | deleterious(0.04) | possibly_damaging(0.721) | TCGA-AN-A046-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD | |
SEZ6L2 | SNV | Missense_Mutation | c.2257G>C | p.Gly753Arg | p.G753R | protein_coding | deleterious(0) | probably_damaging(0.999) | TCGA-AN-A0AJ-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD | ||
SEZ6L2 | SNV | Missense_Mutation | rs375292147 | c.2293N>A | p.Ala765Thr | p.A765T | protein_coding | deleterious(0.05) | benign(0.251) | TCGA-AR-A5QP-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Hormone Therapy | tamoxiphen | SD | |
SEZ6L2 | SNV | Missense_Mutation | rs763100339 | c.518G>T | p.Cys173Phe | p.C173F | protein_coding | deleterious(0) | probably_damaging(0.989) | TCGA-D8-A1XQ-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD | |
SEZ6L2 | SNV | Missense_Mutation | rs764439495 | c.2516N>A | p.Arg839Gln | p.R839Q | protein_coding | deleterious(0.04) | possibly_damaging(0.721) | TCGA-E2-A15K-06 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | adriamycin | SD | |
SEZ6L2 | deletion | Frame_Shift_Del | c.964delC | p.Leu322CysfsTer49 | p.L322Cfs*49 | protein_coding | TCGA-E9-A22G-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | doxorubicin | SD | ||||
SEZ6L2 | SNV | Missense_Mutation | novel | c.2412G>T | p.Glu804Asp | p.E804D | protein_coding | tolerated(0.1) | benign(0.359) | TCGA-2W-A8YY-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Chemotherapy | cisplatin | CR | |
SEZ6L2 | SNV | Missense_Mutation | rs777700133 | c.1768G>A | p.Ala590Thr | p.A590T | protein_coding | tolerated(0.1) | possibly_damaging(0.467) | TCGA-2W-A8YY-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Chemotherapy | cisplatin | CR | |
SEZ6L2 | SNV | Missense_Mutation | rs777993672 | c.773G>A | p.Arg258Gln | p.R258Q | protein_coding | deleterious(0) | probably_damaging(0.982) | TCGA-2W-A8YY-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Chemotherapy | cisplatin | CR |
Page: 1 2 3 4 5 6 7 8 9 10 11 12 |
Top |
Related drugs of malignant transformation related genes |
Identification of chemicals and drugs interact with genes involved in malignant transfromation |
(DGIdb 4.0) |
Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
Page: 1 |